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Abstract
Background: The aim of this study was to investigate the prevalence of osteoporosis in rheumatoid arthritis (RA)
patients and to analyze the risk factors in these patients using the KORean Observational study Network for Arthritis
(KORONA) database.
Methods: Among the RA patients in the KORONA who were recruited between July 2009 and December 2011,
postmenopausal women with bone mineral density (BMD) results within one year from the time of KORONA
enrollment were included in this study. The baseline characteristics of patients in three groups, defined by BMD
results, were compared. The BMD measurement rates and prevalence of osteoporosis in the study patients were
calculated in accordance with age and gender subgroups. Multivariable logistic regression analysis was used to
explore the association between osteoporosis and demographics and disease-related risk factors.
Results: Of 1322 postmenopausal woman patients with RA in whom BMD was measured within one year of study
enrollment, 619 patients (46.8 %) were in the osteoporosis group (T-score ≤ −2.5 SD). RA patients with osteoporosis
had a higher frequency of previous fractures than those in other groups, especially fractures of the femur (p = 0.004)
and wrist (p = 0.042). Advanced age (≥70 years; OR = 2.28, 95 % CI: 1.40–3.58), lower body mass index (<25; OR = 2.14,
95 % CI:1.52–3.02), longer disease duration (≥10 years; OR = 1.46, 95 % CI: 1.07–2.00), higher cumulative glucocorticoid
dose (OR = 1.03, 95 % CI: 1.01–1.05), and higher Health Assessment Questionnaire score (OR = 1.37, 95 % CI:1.11–1.69)
were independent risk factors for osteoporosis.
Conclusion: A large percentage (90.8 %) of RA patients enrolled in the KORONA cohort had osteoporosis and
osteopenia. Nevertheless, BMD measurement rates in this population remained low, despite high risk groups of
fractures.
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Background
Osteoporosis is a well-known extra-articular complica-
tion in patients with rheumatoid arthritis (RA) [1]. It is
more common in patients with RA than in the general
population, due to active systemic inflammation, the
use of corticosteroids, and lack of mobility [2, 3]. As a
result, patients with RA are at increased risk of fractures,
an outcome that impairs quality of life and leads to
mortality [4, 5].
The prevalence of osteoporosis in RA patients is re-
ported to be approximately twice that in the general
population [4]. The frequency of generalized osteoporosis
in patients with RA ranges from 12.3 to 38.9 % in the lum-
bar spine and from 6.3 to 36.3 % in the hip [4–6]. Above
all, there is at least a two-fold increase in the risk of verte-
bral fracture (VFs) in RA patients and a higher risk, up to
six-fold, has been reported in patients with long-standing
disease [6, 7]. However, studies on early RA have shown
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that VFs can be observed in the first year of the disease.
As a result, approximately one-third of women with RA
report a fracture within five years of follow up [8].
The risk factors for osteoporosis and osteoporotic frac-
tures in RA patients are age, disability, low body mass index
(BMI), previous non-vertebral fracture, long-standing
disease, and glucocorticoids. In particular, regardless of
additional risk factors, patients taking glucocorticoids
should be screened for osteoporosis. Although aware-
ness of osteoporosis by healthcare professionals has in-
creased in recent years, it remains underdiagnosed and
undertreated [9].
The increased risk of osteoporosis in RA patients is well
reported [1, 2] and may be linked to differences in the dis-
tribution and interactions of genetic and environmental
factors [10, 11]. However, little information is available on
the frequency of osteoporosis and bone mineral density
(BMD) measurement rates in RA patients and the associ-
ated risk factors in South Korea.
Thus, the aims of this study were to investigate the
prevalence of osteoporosis in RA patients and to analyze
the risk factors in these patients using the KORean Obser-
vational study Network for Arthritis (KORONA) database




KORONA was established in July 2009 by the Clinical
Research Center for Rheumatoid Arthritis and funded by
the Ministry of Health and Affairs, South Korea. RA pa-
tients over the age of 18 who satisfied the 1987 American
College of Rheumatology (ACR) classification criteria for
RA [13] were recruited by rheumatologists from 23 centers
across South Korea as part of KORONA. Among those
patients, only postmenopausal women were enrolled in
this study. A total of 3531 patients with RA were recruited
between July 2009 and December 2011, and 1322 post-
menopausal women whose BMD examination results were
available within one year from the time of KORONA
enrollment were included in this study (Fig. 1). The
KORONA protocol was approved by the institutional
review boards of Hanyang University Hospital and all
participating hospitals, and informed consent was ob-
tained from all patients before registration.
Data collection
Demographic and clinical features
All participants in this research completed an initial
questionnaire to establish their demographic profile,
medical history, and disease-specific outcomes. Disease
activity was evaluated by physicians, and joint assessments
were made by rheumatologists or well-trained health pro-
fessionals. These evaluations, together with laboratory test
results, prescription information (glucocorticoids—current
and cumulative doses), and patient self-evaluation (history
of previous fracture, fracture site, smoking, and alcohol
intake), were incorporated into the KORONA database.
Laboratory data to identify the characteristics of RA
(anti-cyclic-citrullinated protein antibody (ACPA) and
rheumatoid factor (RF)) were obtained, and disease activity
was monitored using erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP). Disease Activity Score 28
using erythrocyte sedimentation rate (DAS28-ESR) and
Health Assessment Questionnaire (HAQ) results were used
to assess health-related outcomes. The DAS28-ESR index
combines information regarding the number of swollen
and tender joints, as well as a measure of general health
and acute phase response (ESR) [14]. The HAQ is a model
of patient-oriented outcome assessment and is based on
the following five patient-centered dimensions: disability,
pain, medication effect, cost of care, and mortality [15].
Fig. 1 Flow diagram for the identification of study population in the KORONA. DXA, dual X-ray absorptiometry
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BMD data collection
Only patients with BMD data available within one year
from the time of recruitment were included in this
study. BMD measurements were carried out with Holo-
gic QDR (Waltham, MA, USA) and GE Lunar Prodigy
(Madison, WI, USA) systems, using the manufacturers’
standard scan and positioning protocols. Trained techni-
cians at each center performed the scanning according
to a standardized protocol. Each center followed the
manufacturers’ procedures to check the stability and ac-
curacy of their equipment using regular measurements
of European phantom. However, no cross-calibration was
performed on any of the systems. The reference BMD
values use Korean data provided by the manufacturers.
Diagnoses of osteopenia and osteoporosis were made
using calculations based on the World Health Organization
(WHO) T-score criteria (−1.0 to −2.5 SD and ≤ −2.5 SD)
[16]. In addition, according to the recommendation of the
International Society for Clinical Densitometry, osteopor-
osis was diagnosed based on the lowest T-score among the
three sites (lumbar spine, femoral neck, and total hip) [16].
Statistical analysis
Baseline characteristics were compared among three pa-
tient groups (normal, osteopenia, and osteoporosis) defined
according to BMD results (Table 1). Chi-square, Kruskal-
Wallis test and one-way ANOVA were used for categorical,
skewed continuous and continuous variables, respectively.
BMD measurement rates within one year from the time of
enrollment were analyzed, and the frequency of osteopor-
osis in the study patients was calculated for age subgroups
(Table 2). Lumbar spine, femoral neck, and total hip
T-scores in the enrolled RA patients were presented as
the mean and standard deviation (SD) according to the
patient’s age (Table 3). Finally, multivariable logistic
regression analysis was used to explore the association
between osteoporosis and the demographics and disease-
related risk factors listed in Table 1 (Table 4). Some vari-
ables (HAQ, DAS28-ESR, ESR and CRP) that were not
normally distributed were log-transformed to approximate
a normal distribution for analysis. All analyses were per-
formed using SPSS software (version 17.0, SPSS Inc., IL,
USA). Results were considered statistically significant
when p values were less than 0.05.
Results
Demographic and clinical features
The demographic and clinical features of the RA patients
are presented in Table 1. There were 1322 postmeno-
pausal women with BMD results available within one year
Table 1 Demographic and clinical features of study population
Total Osteoporosis Osteopenia Normal p
(N = 1322) (N = 619) (N = 582) (N = 121)
Age 61.2 ± 8.2 63.7 ± 8.2 59.8 ± 7.3 55.1 ± 6.6 <0.001
BMI (kg/m2) 22.9 ± 3.1 22.0 ± 3.2 23.4 ± 2.9 24.7 ± 3.3 <0.001
Disease duration (yrs) 12.1 ± 9.9 13.9 ± 10.6 10.9 ± −9.3 9.1 ± −8.7 <0.001
Previous fracture (N, %)
Vertebrae 40 (3.0) 23 (1.7) 17 (1.3) 0 (0.0) 0.090
Femur 24 (1.8) 19 (1.4) 5 (0.4) 0 (0.0) 0.004
Wrist 66 (5.0) 38 (2.9) 27 (2.0) 1 (0.1) 0.042
Upper arm 16 (1.2) 11 (0.8) 5 (0.4) 0 (0.0) 0.154
Othersa 171 (12.9) 95 (7.2) 65 (74.9) 11 (0.8) 0.041
Use of GC (N, %) 1027 (77.7) 498 (80.5) 439 (75.4) 90 (74.4) 0.074
Current dose of GC (mg/day) 4.3 ± 2.5 4.4 ± 2.7 4.2 ± 2.4 4.4 ± 2.1 0.581
Cumulative dose of GC (g*mo)b 5.4 ± 7.0 6.7 ± 7.7 4.4 ± 6.4 3.6 ± 6.1 <0.001
HAQ (0–3) 0.9 (1.0) 1.0 (1.1) 0.8 (0.9) 0.6 (0.9) <0.001
DAS28-ESR 4.0 (1.8) 3.9 (1.9) 4.0 (1.8) 3.8 (1.5) 0.120
ESR (mm/h) 26.0 (32.0) 25.0 (32.0) 28.0 (33.0) 24.0 (27.0) 0.240
CRP (mg/dL) 0.3 (0.8) 0.3 (0.8) 0.3 (0.9) 0.2 (0.5) 0.058
RF, positivity (N, %) 1158 (87.7) 545 (88.2) 510 (87.6) 103 (85.1) 0.644
ACPA, positivity (N, %) 899 (84.3) 395 (83.5) 418 (85.5) 86 (81.9) 0.551
Values shown are median (interquartile range), mean ± standard deviation and frequency (percentage)
BMI bone mass index, BMD bone mineral density, GC glucocorticoid, HAQ health assessment questionnaire, DAS 28-ESR Disease Activity Score 28 using ESR,
ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic-citrullinated protein antibody
aNasal bone, clavicle, shoulder, scapula, rib, hand, pelvic bone, ankle, feet, coccyx
bDose of glucocorticoids according prednisolone × 30 ×months/1000
Lee et al. BMC Musculoskeletal Disorders  (2016) 17:98 Page 3 of 7
from the time of recruitment. The mean ages of these pa-
tients in the osteoporosis, osteopenia, and normal groups
were 63.7 (8.2) years, 59.8 (7.3) years, and 55.1 (6.6) years,
respectively; the patients with osteoporosis were signifi-
cantly older than those with osteopenia or normal BMD
(p < 0.001). Disease duration in the study population was
12.1 ± 9.9 years (mean). The RA patients with osteoporosis
were older (p < 0.001) and had longer disease duration
(p < 0.001), lower BMI (p < 0.001), and higher cumulative
dosage of glucocorticoid (p < 0.001) than the patients in the
other groups. The osteoporosis patients also had a higher
frequency of previous fractures than the patients in the
other groups, especially fractures of the femur (p = 0.004)
and wrist (p = 0.042). HAQ scores (median and interquar-
tile range) were significantly higher [1.0 (1.1)] in the osteo-
porosis patients than in the osteopenia patients [0.8 (0.9)]
and the normal patients [0.6 (0.9)] (p < 0.001). Disease
activity-related factors such as DAS28-ESR (p = 0.120), ESR
(p = 0.240), CRP (p = 0.058), current smoking (p = 0.300),
and alcohol intake (p = 0.067) did not differ among the
three groups.
Frequency of osteoporosis based on BMD
Among the 1322 patients with BMD data, 619 (46.8 %),
582 (44.0 %), and 121 (9.1 %) patients were in the osteo-
porosis, osteopenia, and normal groups, respectively.
The number of osteoporosis patients in the 60–69 years
age group was the highest (n = 285, 46.0 %) (Table 2). In
addition, osteoporosis occurred in 31.2 % in the lumbar
spine, 29.9 % in the femoral neck, and 18.5 % in total
hip. The lumbar spine, femoral neck, and total hip T-scores
in the entire cohort were analyzed according to each age
subgroup. The femoral neck T-scores were lowest among
the three sites in all age subgroups (Table 3).
Risk factors for osteoporosis
The multivariable logistic regression modeling attempted
to use all demographic and disease-related factors asso-
ciated with the outcome in Table 1. As a result, ad-
vanced age (≥70 years; OR = 2.28, 95 % CI: 1.40–3.58),
BMI < 25 (OR = 2.14, 95 % CI: 1.52–3.02), longer disease
duration (≥10 years; OR = 1.46, 95 % CI: 1.07-2.00),
higher cumulative dose of glucocorticoids (OR = 1.03,
95 % CI: 1.01–1.05), and higher HAQ score (OR = 1.37,
95 % CI: 1.11–1.69) were statistically significant inde-
pendent factors associated with osteoporosis. However,
Table 2 The frequency of osteoporosis at either the femoral neck or lumbar spine BMD with RA patients
Age Total BMD measurement rates Osteoporosis Osteopenia Normal
(N) (N, %) (N, %) (N, %) (N, %)
25–49 238 75 (5.7) 18 (2.9) 38 (6.5) 19 (15.7)
50–59 1267 503 (38.1) 174 (28.1) 257 (44.2) 72 (59.5)
60–69 1053 542 (41.0) 285 (46.0) 230 (39.5) 27 (22.3)
70–79 351 184 (13.9) 125 (20.2) 56 (9.6) 3 (2.5)
≥80 31 18 (1.4) 17 (2.8) 1 (0.2) 0 (0.0)
Total (N, %) 2940 1322 (45.0) 619 (46.8) 582 (44.0) 121 (9.2)
Table 3 T-scores in patients with RA according to age groups
Age Lumbar spinea Femoral neck Total hip
(N = 1317) (N = 1277) (N = 1266)
40–49 −0.9 ± 1.3 −1.2 ± 1.1 −0.6 ± 1.2
50–59 −1.6 ± 1.1 −1.6 ± 1.0 −1.1 ± 1.1
60–69 −1.9 ± 1.4 −2.1 ± 1.0 −1.6 ± 1.2
70–79 −2.1 ± 1.3 −2.5 ± 0.9 −2.1 ± 1.1
≥80 −2.9 ± 0.9 −2.6 ± 1.0 −2.7 ± 0.9
Total −1.8 ± 1.3 −1.9 ± 1.1 −1.4 ± 1.2
aAverage of T-score of L2-L4
Table 4 multivariale logistic regression analysis on risk factors of
osteoporosis in RA patients
Risk factors OR 95 % CI p
Age
< 70 yrs 1
≥ 70 yrs 2.28 1.40–3.58 <0.001
BMI (Kg/m2)
≥ 25 1
< 25 2.14 1.52–3.02 <0.001
Disease duration (yrs)
< 10 yrs 1
≥ 10 yrs 1.46 1.07–2.00 0.032
Cumulative dose of GC (g) 1.03 1.01–1.05 0.009
RF, Positivity 0.86 0.55–1.36 0.690
ACPA, positivity 1.00 0.65–1.52 0.718
HAQ score 1.37 1.11–1.69 0.003
DAS28-ESR 0.69 0.39–1.24 0.217
ESR (mm/h) 0.94 0.75–1.18 0.571
CRP (mg/dL) 1.01 0.89–1.16 0.853
OR odds ratios, CI confidence interval, BMI bone mass index, GC glucocorticoid,
RF rheumatoid factor, ACPA anti-cyclic-citrullinated protein, HAQ health assessment
questionnaire, DAS 28-ESR Disease Activity Score 28 using ESR, ESR erythrocyte
sedimentation rate, CRP C-reactive protein
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disease activity-associated factors (ESR, CRP, and DAS28-
ESR), RF and ACPA showed no independent association
with osteoporosis (Table 4).
Discussion
The aim of this study was to investigate the frequency of
and risk factors for osteoporosis in Korean postmeno-
pausal women with RA. The frequency of osteoporosis
was 46.8 %. This frequency is higher in comparison to some
other studies, which reported a prevalence of 22–24 %
[17, 18]. However, a high prevalence (50 %) of osteoporosis
was shown in a large Italian multicenter cross-sectional
study that included 925 female RA patients [5]. In another
study of postmenopausal women and men ≥50 years of
age with seropositive RA in South Korea, 121 (52 %) of
the 234 patients had osteoporosis [19]. This frequency was
higher than that of the general population of females aged
≥50 years. In the Fourth Korea National Health and Nutri-
tion Examination Survey database, it was estimated that in
the general Korean female population aged ≥50 years,
39.1 % had osteoporosis while 43.4 % had osteopenia [20].
Thus, the prevalence rate of osteoporosis in RA patients
varies among studies. This diversity can be explained by
the use of different age groups in the study populations,
the menopausal status of the participants, and the use of
glucocorticoids.
BMD measurement is required in all RA patients due
to the increased risk of fractures. However, a significant
percentage of RA patients with fracture risk do not undergo
BMD testing despite regular visits to rheumatologists. Of
the 3531 RA patients enrolled in our study, only 41.2 %
had BMD data. According to a study by the Consor-
tium of Rheumatology Researchers of North America
(CORRONA), of the RA patients in the database with
at least a one-year follow up, 45 % reported dual-energy
X-ray absorptiometry (DXA) data upon study entry. Fur-
thermore, of the 2717 RA patients with at least a one-year
follow up without reported DXA data at enrollment in the
CORRONA study, 297 (11 %) patients reported undergo-
ing DXA during the first year of follow up [21]. Although
the CORRONA study included patients <50 years of age,
the BMD measurement rate was higher than in this study.
The patients in this study had a lower BMD measurement
rate despite being older at enrollment. This finding should
motivate Korean clinicians to carry out awareness and
health education programs in these patients to improve
the prevention, diagnosis, and treatment of osteoporosis.
Risk factors for developing osteoporosis in patients with
RA include not only the use of glucocorticoids, high disabil-
ity scores, low body weight, and age, but also RF status; the
frequency of osteoporosis and reduced bone mass is higher
in RF (+) patients. In our study, older age (≥70 years),
low BMI (<25), longer disease duration (≥10 years),
higher HAQ score, and higher cumulative glucocorticoid
dose were significantly associated with osteoporosis. RF,
ACPA, and the use of glucocorticoids were not significantly
associated with osteoporosis (Table 1). Loss of BMD corre-
lates with cumulative glucocorticoid dose, and a correlation
has also been established between fracture risk and daily
glucocorticoid dose [22]. A 30–50 % increase in fracture
risk has been documented in patients receiving long-term
glucocorticoid therapy in both cross-sectional and longitu-
dinal studies [22, 23]. However, glucocorticoid therapy
(used for controlling inflammation) had a positive effect on
BMD in a placebo-controlled study conducted on RA pa-
tients [24, 25]. This effect could contribute to variability of
BMD changes in response to glucocorticoid therapy. In our
study, the use of glucocorticoids was not associated with
osteoporosis; however, cumulative glucocorticoid dose was
significantly associated with osteoporosis. Independent of
RA, risk factors such as older age and low BMI are consist-
ent with those in the general population [26]. However, dis-
ease activity (inflammation), lack of mobility, and treatment
with corticosteroids, especially a high cumulative dose, are
the main factors that increase the risk of osteoporotic frac-
tures, on top of the background fracture risk based on ad-
vanced age, low BMI, and female gender, among others
[27]. In our study, cigarette smoking and alcohol consump-
tion were investigated as environmental factors; however,
these factors were not found to be significantly associated
with osteoporosis.
Fracture risk is highest among women with osteoporosis.
However, many fractures occur in women with BMDs
above the WHO threshold of −2.5 In a large cohort study,
82 % of women who sustained osteoporotic fractures of the
wrist or forearm, hip, rib, or spine within one year after per-
ipheral BMD testing had T-scores greater than −2.5 [28]. In
the current study, the number of osteopenic patients
(44.8 %) was comparable to that of osteoporotic patients
(44.9 %). Nevertheless, no guidelines have yet been estab-
lished for osteopenia patients in South Korea. Therefore,
regular BMD screening and fracture risk assessment (such
as Fracture Risk Assessment (FRAX®) is needed in RA
patients, the high risk group for fractures [28].
To the best of our knowledge, this is the first study to
investigate the prevalence of osteoporosis in RA patients
using a large nationwide cohort (KORONA) in Korea.
The numerous centers, both physician-derived and
patient-derived outcomes, well controlled data, and use
of a “real-world” cohort are the strengths of the study
[12]. This study has a number of limitations. First, we
cannot exclude the possibility of patient selection bias,
because the 23 South Korean centers participating in
this study were tertiary referral centers. The patients
enrolled in this study had higher disease activity and
functional disability than individuals not enrolled in this
study. Therefore, BMD measurement rates in this study
cannot represent the real rate of DXA in our country.
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Second, only patients with BMD data available within
one year from the time of recruitment were included in
this study. As a result, only about one-third of the
population could be included in the analysis of risk factors
for osteoporosis including BMD. Third, no phantom
cross-calibration was performed among study centers.
However, the centers were monitored with their local
quality control phantoms and were found to be stable and
calibrated to their manufacturer’s standards. Fourth, we
used a cross-sectional study design; hence, it was not pos-
sible to make any cause–effect inferences about the rela-
tionship between RA characteristics and BMD. Therefore,
further studies are needed to analyze the risk factors for
osteoporotic fractures and anti-osteoporotic medication.
Conclusions
We found that older age (≥70 years), low BMI (<25),
longer disease duration (≥10 years), higher HAQ score,
and higher cumulative glucocorticoid dose were signifi-
cantly associated with osteoporosis. These findings were
not markedly different from those of previous studies. A
large percentage (90.8 %) of RA patients enrolled in the
KORONA cohort had osteoporosis and osteopenia. BMD
measurement rates in this population remain low, despite
being a high-risk group for osteoporotic fractures.
Abbreviation
BMD: bone mineral density; DXA: dual X-ray absorptiometry;
KORONA: KORean Observational study Network for Arthritis;
WHO: World Health Organization.
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